Wegovy (semaglutide) is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical activity for adults and adolescents aged 12 years old or above with obesity or adults with overweight in the presence of at least one related health condition
One hard exclusion: Medicare, Medicaid, and TRICARE beneficiaries are barred by federal anti-kickback law even when paying cash, so their practical path is a documented-need 503A compounded provider
Injection site reactions are common but usually mild
The drugs are already being investigated as treatments for certain muscle- or bone-related conditions, but Regeneron reasoned that they could also be used to proactively prevent muscle loss while taking a GLP-1
Some patients may also receive GLP-2, another hormone targeting the digestive system, which plays a key role in metabolic health
Management: Avoid or limit grapefruit products unless advised by your doctor